acetyl-dl-leucine has been researched along with Parkinson Disease in 1 studies
acetylleucine: used for treating vestibular-related imbalance and vertigo
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Xu, Z | 1 |
Lian, C | 1 |
Pan, L | 1 |
Lai, W | 1 |
Zhang, F | 1 |
Peng, L | 1 |
Zhou, S | 1 |
Zhao, G | 1 |
Yang, X | 1 |
Zhang, G | 1 |
Tan, Z | 1 |
Wang, Y | 1 |
1 other study available for acetyl-dl-leucine and Parkinson Disease
Article | Year |
---|---|
N-acetyl-L-leucine protects MPTP-treated Parkinson's disease mouse models by suppressing Desulfobacterota via the gut-brain axis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Gut Axis; Disease Models, Animal; Dopam | 2023 |